Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center

Journal of Clinical Apheresis

Volumn 27, Issue 4, 2012, Pages 178-182

  Sigle, Joerg Peter ^a   Medinger, Michael ^a   Stern, Martin ^b   Infanti, Laura ^a   Heim, Dominik ^b   Halter, Joerg ^b   Gratwohl, Alois ^b   Buser, Andreas ^a  

^a Blood Transfusion Centre   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

apheresis platelets; change control; hematopoietic stem cell recipients; transfer production

Indexed keywords

THROMBOCYTE CONCENTRATE;

ARTICLE; HUMAN; PRODUCTIVITY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SHELF LIFE; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; UNIVERSITY HOSPITAL;

BLOOD TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS; PROSPECTIVE STUDIES; QUALITY CONTROL; RED CROSS; SWITZERLAND;

EID: 84864715053     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21214     Document Type: Article

References (21)

1. Keitel S, editor. Guide to the preparation, use and quality assurance of blood components. Strasbourg: European Directorate for the Quality of Medicines and HealthCare. 2010. pp 189-224.
2. Swiss Guidelines BSD SRK, Chapter 18B. Specifications platelet concentrates. Version 1.7. 2010.
3. Speck B, Nissen C, Tichelli A, Roth J, Dazzi H, Stebler CH, Wernli M, Signer E, Gratwohl A,. Bone marrow transplantation in Basel: single center experience from 1973 to 1989. Clin Transpl 1989; 1989: 115-122.
4. Favre G, Fopp M, Gmür J, Tichelli A, Fey MF, Tobler A, Schatzmann E, Gratwohl A,. Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol 1993; 67: 153-160. (Pubitemid 23295589)
5. Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, Meyer-Monard S, Halter J, Tichelli A, Gratwohl A,. Patient and product factors affecting platelet transfusion results. Transfusion 2008; 48: 681-687. (Pubitemid 351430354)
6. Infanti L, Job S, Stebler C, Ruesch M, Gratwohl A, Irsch J, Lin L, Buser A,. Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: the first Swiss experience. Transf Aph Sci 2011; 45: 175-181.
7. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-1541. (Pubitemid 39166535)
8. Slopecki A, Smith K, Moore S,. The value of Good Manufacturing Practice to a Blood Service in managing the delivery of quality. Vox Sang 2007; 92: 187-196. (Pubitemid 46365023)
9. Motschman TL, Jett BW, Wilkinson SL,. Quality systems: Theory and Practice. In:, Roback JD, editor. Technical Manual. Bethesda (MD): AABB. 2008. pp 1-40.
10. Enein AA, Hussein EA, El Shafie S, Hallouda M,. Factors affecting platelet yield and their impact on the platelet increment of patients receiving single donor PLT transfusion. J Clin Apher 2007; 22: 5-9. (Pubitemid 46407053)
11. Fontana S, Mordasini L, Keller P, Taleghani BM,. Prospective, paired crossover comparison of multiple, single-needle plateletpheresis procedures with the Amicus and Trima Accel cell separators. Transfusion 2006; 46: 2004-2010. (Pubitemid 44631609)
12. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ,. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48: 1447-1458.
13. Kerkhoffs JL, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de Vries RR, Barge R, van Rhenen DJ, Brand A,. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108: 3210-3215.
14. Kelsey P,. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23. (Pubitemid 36819334)
15. Arber C, Bertrand G, Halter J, Boehlen F, Kaplan C, Gratwohl A,. Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay. Br J Haematol 2007; 139: 159-161. (Pubitemid 47389928)
16. Norris JM, Dikeman J, Greene D, Hathaway E,. Managing change. Transfusion 2009; 49: 2524-2535.
17. Stank T, Brzica M, Ficenec J,. The benefits of supply-chain integration using a third-party generator. Transfusion 2009; 49: 2536-2538.
18. Wilding R, Cotton S, Dobbin J, Chapman J, Yates N,. Time-based analysis of the apheresis platelet supply chain in England. Vox Sang 2011; 101: 247-249.
19. Gerdtham UG, Lothgren M, Tambour M, Rehnberg C,. Internal markets and health care efficiency: a multiple output stochastic frontier analysis. Health Econ 1999; 8: 151-164. (Pubitemid 29178567)
20. Veihola M, Aroviita P, Linna M, Sintonen H, Kekomäki R,. Variation of platelet production and discard rates in 17 blood centers representing 10 European countries from 2000 to 2002. Transfusion 2006; 46: 991-995. (Pubitemid 43800918)
21. Fuller K, Uglik KM, Braine HG, King KE,. A comprehensive program to minimize platelet outdating. Transfusion 2011; 51: 1469-1476.